Grufity logo
Grufity logo
ALLR

ALLR - Allarity Therapeutics, Inc. Stock Price, Fair Value and News

$1.22-0.01 (-0.81%)
Market Closed as of 31 Jul 2026, 04:00 pm ET

Price Targets

ALLR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALLR Price Action

Last 7 days

2.5%

Last 30 days

-8.3%

Last 90 days

-6.1%

Trailing 12 Months

17.3%

ALLR RSI Chart

ALLR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALLR Valuation

Market Cap

19.4M

Price/Earnings (Trailing)

-1.73

Price/Sales (Trailing)

59.17

EV/EBITDA

0.08

Price/Free Cashflow

-1.14

ALLR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ALLR Fundamentals

ALLR Revenue

Revenue (TTM)

320.0K

ALLR Earnings

Earnings (TTM)

-11.2M

Earnings Growth (Yr)

-0.66%

Earnings Growth (Qtr)

18.47%

ALLR Profitability

EBT Margin

-3504.69%

Return on Equity

-162.56%

Return on Assets

-32.21%

Free Cashflow Yield

-87.9%

ALLR Investor Care

Shares Dilution (1Y)

42.74%

Revenue & Growth

How Allarity Therapeutics, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
2025---320.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Allarity Therapeutics, Inc.

ALLR
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
0
 CEO
 WEBSITEallarity.com
 SECTORHealthcare
 INDUSTRYBiotechnology

Allarity Therapeutics, Inc. Frequently Asked Questions

ALLR is the stock ticker symbol of Allarity Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jul 31 2026, market cap of Allarity Therapeutics, Inc. is 19.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jul 31 2026, ALLR's PE ratio (Price to Earnings) is -1.73 and Price to Sales (PS) ratio is 59.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALLR PE ratio will change depending on the future growth rate expectations of investors.